Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all.

58 – 60 Biologics such as rituximab have demonstrated benefits in SSc-ILD by improving both restriction and diffusion capacity in a meta-analysis, 14 and subcutaneous tocilizumab showed a trend towards stabilisation of FVC. 61 , 62 Particularly, tocilizumab seems to stabilise lung function decline in patients with early SSc-ILD and elevated acute-phase reactants, 63 and in patients with positive anti-topoisomerase antibodies. 64 Nintedanib managed to slow down FVC decline, and can be a po

also in 53,322 other papers